Angiogenesis inhibitors are expected to be used in the therapies of several different cancers-colon, breast, prostate, ovarian, head & neck/esophageal, pancreatic and lung among others. CTO is a small molecule and it can be given orally. In addition, CTO is a synthetic oral inhibitor of calcium influx and has demonstrated anti-invasive and anti-proliferative properties. Most importantly, it will be cost effective in comparison to comparable biological angiogenesis inhibitors.
In Phase I CTO demonstrated activity in refractory tumors which were pretreated with targeted and non-targeted agents. Based on those results, CTO is being developed in several Phase II trials, ex. malignant ghomas and glioblastoma, ovarian cancer, non-small cell lung cancer, head, neck and metastatic colorectal cancer.